What the MHRA changed
On 29 January 2026 the MHRA updated the product information for every GLP-1 receptor agonist and dual GLP-1/GIP receptor agonist authorised in the UK - dulaglutide, exenatide, liraglutide, semaglutide and tirzepatide - to highlight the potential risk of severe acute pancreatitis, including rare reports of necrotising and fatal cases. The update was published in Drug Safety Update (volume 19, issue 6) and asks prescribers to remain alert to the signs of acute pancreatitis in patients taking these medicines.
What the UK reporting data show
The MHRA's accompanying guidance noted that, between 2007 and October 2025, it had received 1,296 UK Yellow Card reports of pancreatitis associated with GLP-1 receptor agonists. Yellow Card reports record suspicions, not confirmed causal links: a report states that a patient on the medicine developed the event, not that the medicine caused it. The rise in reports tracked the very large increase in prescribing - an estimated 1.6 million adults in England, Wales and Scotland used a GLP-1 medicine for weight loss between early 2024 and early 2025.
What the randomised trials show
The regulatory warning sits alongside a mixed trial literature. Pooled analyses of placebo-controlled randomised trials of semaglutide and tirzepatide have not shown a statistically significant increase in acute pancreatitis versus placebo, and a multicentre analysis published in the American Journal of Gastroenterology in 2026 found that GLP-1 receptor agonist use did not increase the risk of acute pancreatitis, and was associated with lower complication rates among patients with type 2 diabetes who developed it. A living systematic review and meta-analysis posted to medRxiv in March 2026 - a preprint, so not yet peer-reviewed - reached a similarly cautious conclusion. Acute pancreatitis has recognised non-drug causes, gallstones first among them, which complicates attribution in any single case.
Reading the signal honestly
Three statements are consistent, not contradictory: acute pancreatitis is a recognised, uncommon risk listed on the product information of these medicines; post-marketing reports describe rare severe and fatal cases; and randomised-trial data have not demonstrated a clear increase in risk. A safety update is not a finding that a medicine is unsafe, and it does not change the licensing status of any product named here.
Where this leaves UK readers
Semaglutide, tirzepatide, liraglutide, exenatide and dulaglutide are prescription-only medicines in the UK, authorised for defined indications under the Human Medicines Regulations 2012. They are not research-use-only laboratory compounds, and nothing in this article is a guide to their use. Anyone prescribed one of these medicines who develops severe, persistent abdominal pain - particularly pain radiating to the back with nausea or vomiting - should treat it as a medical emergency and seek urgent medical attention; a suspected adverse reaction can be reported to the MHRA through the Yellow Card scheme. Research compounds discussed elsewhere on this site remain research-use-only.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.